Rein Therapeutics, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Rein Therapeutics, Inc. (RNTX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$10.62 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-26
- Rein Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$10.62M.
- Rein Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$13.49M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$10.62M 10-K · filed 2026-03-26 |
| 2024-12-31 | -$13.49M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |